Perimenopause: What are the symptoms, and why are women calling it ‘cougar puberty?'
'I assumed it was all related to stress,' the hospital administrator from the US state of Texas told Euronews Health. But even when life calmed down, the symptoms persisted.
'I reached out to my doctor for some blood work, but all my hormones came back normal, so I was told to wait,' added Amanda, who requested that only her first name be used. 'Then the cycle would begin again'.
It was only in the last month – a year since she first went to the doctor – that her blood test results showed she has low ovary production. This confirmed what Amanda had been suspecting: her body was in perimenopause.
Related
Women missing work due to painful periods and endometriosis costing UK €13 billion a year
What is perimenopause?
Menopause marks the end of a woman's reproductive cycle, defined by the absence of a period for 12 consecutive months. On average, women experience menopause between ages 45 and 55, according to the World Health Organization (WHO).
The time leading up to menopause is known as perimenopause, during which hormone levels begin to fluctuate and decline. Symptoms include poor sleep, hot flushes, brain fog, anxiety, mood swings, and irregular periods, the UK's National Health Service (NHS) states.
Many friends would dismiss my concerns that I was menopausal because 'they're older and they're fine'.
'Around one in 30 women under the age of 40 are menopausal, meaning that many young women will also be perimenopausal,' said Dr Louise Newson, a menopause specialist and founder of the Balance app, which provides personalised support for women with menopausal symptoms.
'Factors such as family history, medical conditions, or treatments like surgery or chemotherapy can all lead to menopause occurring at a younger age,' Newson told Euronews Health.
Related
Women's viagra? New testosterone patch for menopause sex drive loss to start clinical trials
Until recently, perimenopause remained under-discussed due to taboos surrounding the subject, according to Newson. This, along with an absence of any official test to diagnose it, has led some women to feel confused, alone, and belittled by others about their symptoms.
'Many friends would dismiss my concerns that I was menopausal because 'they're older and they're fine,'' Amanda said.
Delays can be serious. Last year, a UK government report found that women suffering from reproductive health conditions, such as endometriosis, frequently wait years for diagnosis or treatment, in one example of what it called 'medical misogyny'.
Perimenopause symptoms in particular can have a significant impact on wellbeing, with almost 40 per cent of women experiencing moderate to severe hot flushes and night sweats, according to a study published in the Lancet Diabetes & Endocrinology.
Yet still, it remains significantly under-researched, and many women are misdiagnosed with conditions such as depression, anxiety, arthritis, or fibromyalgia, which causes full body pain and fatigue, according to Newson.
That closely mirrors Amanda's experience.
'I went to the doctor multiple times, and they always entertained my requests for testing and appointments. But when nothing would show up, and they'd hear about how stressed I've been, it was mostly dismissed,' said Amanda.
'I don't think they were being intentionally dismissive, but 'stress' really was used as a general explanation for much longer than it should be'.
Related
Girls with healthier diets tend to get their first periods later, researchers say
How is perimenopause treated?
The main treatment for perimenopause is hormone replacement therapy (HRT), which replaces the body's declining levels of oestrogen and progesterone, according to the UK's NHS.
This can be administered via tablets, skin patches, implants, or as a gel or spray for the skin.
Testosterone supplementation can be used as a secondary option in those struggling with fatigue and low libido.
'The type of hormones you need and the doses you're given vary between each woman – it is not a 'one type fits all' prescription,' Newson said.
'Talking through your options with a healthcare professional is really important to ensure you get the right treatment choice for you, depending on your individual circumstances,' she added.
'Cougar puberty' and online destigmatisation
As awareness of menopausal symptoms has grown, women have found recognition and solidarity in openly discussing their experiences online.
Last year, a TikTok user shared that she'd just heard 'the best term' for perimenopause, coining 'cougar puberty'. This humorous rebrand has since gone viral, with others using it to reclaim their experiences and destigmatise the subject.
'Pretty much sums it up, I've been calling it reverse puberty,' reads one TikTok comment. "Cougar puberty... I like the name... try calling ur [sic] hot flashes tropical moments... it sounds like a vacation," said another.
'For too long, perimenopause and menopause were taboo subjects, discussed in whispers or brushed aside as something women simply had to 'get on with,'' Newson said.
'The visibility and shared experiences we're now seeing – especially online – are helping to improve conversations and increase knowledge that should have been part of mainstream healthcare for decades'.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
NHC Reports Second Quarter 2025 Earnings
MURFREESBORO, Tenn., August 08, 2025--(BUSINESS WIRE)--National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended June 30, 2025 totaled $374,910,000 compared to $300,658,000 for the quarter ended June 30, 2024, an increase of 24.7%. The increase in net operating revenues for the second quarter of 2025 compared to the second quarter of 2024 was due to an 9.6% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Management, Inc. ("White Oak"). For the quarter ended June 30, 2025, the reported GAAP net income attributable to NHC was $23,722,000 compared to $26,844,000 for the same period in 2024. Excluding the unrealized gains and losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended June 30, 2025 was $25,710,000 compared to $15,612,000 for the same period in 2024, an increase of 64.7% (*). The GAAP diluted earnings per share were $1.52 and $1.73 for the quarters ending June 30, 2025 and 2024, respectively. Adjusted diluted earnings per share were $1.65 and $1.00 for the quarters ending June 30, 2025 and 2024, respectively (*). (*) - See the tables below that provide a reconciliation of GAAP to non-GAAP items. About NHCAs of August 1, 2025, NHC affiliates operate for themselves and third parties 80 skilled nursing facilities with 10,329 beds. NHC affiliates also operate 26 assisted living communities with 1,413 units, nine independent living communities with 777 units, three behavioral health hospitals, 34 homecare agencies, and 33 hospice agencies. NHC's other services include Alzheimer's and memory care units, pharmacy services, a rehabilitation services company, and providing management and accounting services to third party post-acute operators. Other information about the company can be found on our web site at Non-GAAP Financial PresentationThe Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. Therefore, the Company believes this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Forward-Looking StatementsStatements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q, and 10-K. All forward-looking statements represent NHC's best judgment as of the date of this release. Consolidated Statements of Operations (in thousands, except share and per share amounts) Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Revenues: Net patient revenues $ 363,349 $ 279,918 $ 724,956 $ 565,741 Other revenues 11,561 11,295 23,651 22,648 Government stimulus income - 9,445 - 9,445 Net operating revenues and grant income 374,910 300,658 748,607 597,834 Costs and expenses: Salaries, wages and benefits 226,534 180,076 454,664 363,214 Other operating 91,943 78,154 184,400 155,583 Facility rent 11,328 10,570 22,693 20,918 Depreciation and amortization 11,015 9,338 21,993 19,924 Total costs and expenses 340,820 278,138 683,750 559,639 Income from operations 34,090 22,520 64,857 38,195 Non-operating income 5,132 4,956 9,211 10,641 Interest expense (1,993 ) - (4,099 ) (46 ) Unrealized gains/(losses) on marketable equity securities (5,061 ) 9,124 5,921 23,523 Income before income taxes 32,168 36,600 75,890 72,313 Income tax provision (8,055 ) (9,494 ) (19,487 ) (18,956 ) Net income 24,113 27,106 56,403 53,357 Net income attributable to noncontrolling interest (391 ) (262 ) (476 ) (300 ) Net income attributable to National HealthCare Corporation $ 23,722 $ 26,844 $ 55,927 $ 53,057 Net income per common share Basic $ 1.53 $ 1.74 $ 3.62 $ 3.45 Diluted $ 1.52 $ 1.73 $ 3.59 $ 3.42 Weighted average common shares outstanding Basic 15,462,135 15,391,535 15,450,286 15,371,150 Diluted 15,599,638 15,555,612 15,587,783 15,530,624 Dividends declared per common share $ 0.64 $ 0.61 $ 1.25 $ 1.20 Balance Sheet Data June 30 December 31 (in thousands) 2025 2024 (unaudited) Cash, cash equivalents and marketable securities $ 257,628 $ 216,185 Restricted cash, cash equivalents and marketable securities 169,340 163,795 Current assets 463,227 424,408 Property and equipment, net 676,619 684,289 Total assets 1,562,220 1,524,429 Current liabilities, excluding current long-term debt 261,245 227,297 Current and long-term debt 110,000 137,000 NHC stockholders' equity 1,021,905 980,161 Selected Operating Statistics Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Skilled Nursing Per Diems: Medicare $ 614.85 $ 577.71 $ 613.47 $ 579.81 Managed Care 486.17 447.96 489.30 459.48 Medicaid 286.43 264.49 284.07 264.88 Private Pay and Other 341.34 312.91 339.24 310.31 Average Skilled Nursing Per Diem $ 361.42 $ 338.86 $ 360.78 (1) $ 341.21 (1) Skilled Nursing Patient Days: Medicare 83,615 74,602 169,869 155,758 Managed Care 83,015 62,957 166,661 128,388 Medicaid 368,687 279,504 732,329 561,325 Private Pay and Other 194,202 150,234 378,796 307,677 Total Skilled Nursing Patient Days 729,519 567,297 1,447,655 (1) 1,153,148 (1) (1) NHC exited three skilled nursing facilities in Missouri on March 1, 2024. For the six months ended June 30, 2024, the exited Missouri skilled nursing facilities had an average skilled nursing per diem of $275.64 and 20,267 patient days. The tables below provide reconciliations of GAAP to non-GAAP items (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Net income attributable to National Healthcare Corporation $ 23,722 $ 26,844 $ 55,927 $ 53,057 Non-GAAP adjustments Unrealized (gains)/losses on marketable equity securities 5,061 (9,124 ) (5,921 ) (23,523 ) Operating losses for newly-opened operations not at full capacity - 20 - 20 Gain on sale of property and equipment (3,606 ) - (3,606 ) - Gain on sale of unconsolidated company - - - (1,024 ) Stock-based compensation expense 1,232 1,176 2,260 1,969 Acquisition-related expenses - 2,194 - 2,194 Employee retention credit - (9,445 ) - (9,445 ) Income tax provision/(benefit) on non-GAAP adjustments (699 ) 3,947 1,889 7,750 Non-GAAP Net income $ 25,710 $ 15,612 $ 50,549 $ 30,998 GAAP diluted earnings per share $ 1.52 $ 1.73 $ 3.59 $ 3.42 Non-GAAP adjustments Unrealized (gains)/losses on marketable equity securities 0.32 (0.59 ) (0.38 ) (1.51 ) Gain on sale of property and equipment (0.23 ) - (0.23 ) - Gain on sale of unconsolidated company - - - (0.07 ) Stock-based compensation expense 0.08 0.08 0.14 0.13 Acquisition-related expenses - 0.14 - 0.14 Employee retention credit - (0.61 ) - (0.61 ) Income tax provision/(benefit) on non-GAAP adjustments (0.04 ) 0.25 0.12 0.50 Non-GAAP diluted earnings per share $ 1.65 $ 1.00 $ 3.24 $ 2.00 View source version on Contacts Brian F. Kidd, SVP/CFOPhone: (615) 890-2020
Yahoo
23 minutes ago
- Yahoo
RBL LLC secures investment from Modi Ventures
- Strategic investment to support RBL's mission to launch and scale breakthrough startups - Founder and general partner of Modi Ventures, Sahir Ali, to join RBL board of directors - Modi Ventures' Ali, RBL managing partner Wotton to speak on venture creation at Canaccord Genuity Growth Conference Aug. 12 HOUSTON, Aug. 8, 2025 /PRNewswire/ -- RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical technologies, announced that it has secured an investment from Modi Ventures to support its mission to launch and scale breakthrough startups into clinical-stage companies. In addition, RBL has announced the appointment of Sahir Ali to its board of directors. Ali is the founder and current general partner of Modi Ventures, a leading venture capital firm investing in biology and technology based in Houston. Ali's experience as an accomplished technology and health care leader, investor and adviser will be instrumental in bridging the gap between academic biotech discoveries and the clinical care market. "This investment by Modi Ventures will be instrumental to RBL's growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups," said Paul Wotton, RBL's managing partner. "Sahir's addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission." "The bold thinking and entrepreneurial initiatives coming out of RBL represent an important cornerstone of the rapidly evolving Houston life sciences scene, and I am honored to contribute to this growth by joining this exceptional board," Ali said. "Partnering my new role at RBL with the investment made by Modi can truly help not only build companies but also shape the future of patient care in a collaborative and more efficient way." "Modi Ventures' investment is a strong signal of market validation for the acceleration model we've built into RBL," said Paul Cherukuri, board member of RBL and chief innovation officer of Rice University. "It reflects growing investor confidence in RBL's ability to turn breakthrough science into real-world therapies and in Houston's rise as a global force in biotech innovation." Modi Ventures employs a proprietary financial engineering framework grounded in modern portfolio theory and efficient frontier principles. With $134 million under management, Modi Ventures backs category-defining companies advancing artificial intelligence (AI)-driven drug discovery, diagnostics and engineered therapeutics. The firm also invests in leading funds across the biotech and technology spectrum. A parallel entrepreneur, scientist and innovator, Sahir has led transformative work and built companies across AI, cloud computing and precision medicine. Sahir serves on the board of directors of the Drug Information Association, a leading global life science membership association driving collaboration in drug, device and diagnostics development in pursuit of a healthier world. Sahir will join existing board members Wotton, Cherukuri, Omid Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith and James Watson, an accomplished group of leaders with deep expertise in biotech innovation, clinical translation and venture building who together provide strategic guidance to help drive RBL's continued growth and success. Wotton and Ali will participate in a panel discussion at the Canaccord Genuity 45th annual Growth Conference Aug. 12 to discuss the future of biotech venture creation and the evolving role of academic innovation in company formation. About RBL LLC: RBL LLC is a pioneering biotech venture creation studio based in Houston that is dedicated to accelerating the development of breakthrough medical technologies and therapies through company formation. RBL provides entrepreneurs, researchers and innovators with infrastructure, financial support and strategic guidance as well as access to laboratory space and shared resources in the Texas Medical Center Helix Park. For more information, please visit Media Contact: Russo PartnersDavid Schull or Liz Phillips(347) View original content: SOURCE RBL LLC


Bloomberg
27 minutes ago
- Bloomberg
What If Everything We Think About Obesity Is Wrong?
The US government is approaching the study of obesity all wrong. According to leadership at the Department of Health and Human Services, food companies are to blame — they're engineering their snacks, fast food and sweets to addict us the same way cocaine and nicotine do. Others assessing the epidemic say people overeat because they lack willpower and could stop if they really wanted to.